CN116510009B - 一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 - Google Patents
一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 Download PDFInfo
- Publication number
- CN116510009B CN116510009B CN202310471576.5A CN202310471576A CN116510009B CN 116510009 B CN116510009 B CN 116510009B CN 202310471576 A CN202310471576 A CN 202310471576A CN 116510009 B CN116510009 B CN 116510009B
- Authority
- CN
- China
- Prior art keywords
- hend
- buffer solution
- elution
- aptcd3
- lipo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002114 nanocomposite Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000010828 elution Methods 0.000 claims abstract description 30
- 239000011259 mixed solution Substances 0.000 claims abstract description 30
- 239000010949 copper Substances 0.000 claims abstract description 27
- 239000003054 catalyst Substances 0.000 claims abstract description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 18
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052802 copper Inorganic materials 0.000 claims abstract description 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000007853 buffer solution Substances 0.000 claims abstract description 15
- 229940074404 sodium succinate Drugs 0.000 claims abstract description 15
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000008362 succinate buffer Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims abstract description 8
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims abstract 4
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims description 10
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims description 9
- 150000004699 copper complex Chemical class 0.000 claims description 7
- 230000035484 reaction time Effects 0.000 claims description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 239000012535 impurity Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 23
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- 102100037241 Endoglin Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010036395 Endoglin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TTZOLDXHOCCNMF-UHFFFAOYSA-N 4-fluoro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1O TTZOLDXHOCCNMF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108010083312 T-Cell Antigen Receptor-CD3 Complex Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000001027 hydrothermal synthesis Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供一种hEnd‑AptCD3‑Lipo纳米复合物的制备方法及应用。本发明hEnd‑AptCD3‑Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd‑Apt和CD3单克隆抗体混合,得到混合液;(2)在所述混合液中加入MAL‑PEG2000‑DSPE和铜催化剂,混合均匀,在氮气保护下反应;(3)反应后采用琥珀酸钠缓冲液进行第一次洗脱,再以组氨酸缓冲溶液进行第二次洗脱,制得hEnd‑AptCD3‑Lipo纳米复合物。采用本发明的方法,有效减少产物中杂质残留,进一步保证药物安全性,而且提高抗肿瘤活性。
Description
技术领域
本发明涉及纳米药物领域,特别涉及一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用。
背景技术
Endoglin适配体(hEnd-Apt)能与CD105特异性稳定结合的适配体,能与肝癌细胞HepG2等高表达CD105的细胞特异性结合。人CD3分子是T细胞表面的标记性分子,与T细胞受体(TCR)组成TCR-CD3复合体,在免疫信号传导过程中具有重要作用。基于hEnd-Apt与CD3单克隆抗体修饰纳米脂质体的纳米复合物,即hEnd-AptCD3-Lipo纳米复合物。利用该纳米复合物修饰PD-1-T,,能够增强对HepG2细胞的杀伤活性,即提高其抗肿瘤活性。但现有方法制备产品存在适配体或抗体残留及其他杂质,影响其抗肿瘤活性进一步提高。
发明内容
鉴于此,本发明提出一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用,解决上述问题。
本发明的技术方案是这样实现的:
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:
(1)将hEnd-Apt(Endoglin适配体)和CD3单克隆抗体混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE(二硬脂酰磷脂酰乙醇胺-聚乙二醇2000-马来酰亚胺)和铜催化剂,混合均匀,在氮气保护下反应;
(3)反应后采用琥珀酸钠缓冲液(琥珀酸钠-琥珀酸缓冲液)进行第一次洗脱,再以组氨酸缓冲溶液(组氨酸-醋酸盐缓冲液)进行第二次洗脱,制得hEnd-AptCD3-Lipo纳米复合物。
进一步的技术方案是,步骤(1),所述hEnd-Apt和CD3单克隆抗体的摩尔比为2:0.9~1.1。
进一步的技术方案是,步骤(2),所述MAL-PEG2000-DSPE的质量浓度为9~11g/L,所述混合液和MAL-PEG2000-DSPE的体积比为1:10~11。
进一步的技术方案是,步骤(2),所述铜催化剂为双核铜配合物[Cu2(foac)2(phen)2]·10H2O。
进一步的技术方案是,步骤(2),所述催化剂的加入量为所述混合液质量的1%~2%。
进一步的技术方案是,步骤(2),所述反应时间为15~20h。
进一步的技术方案是,步骤(3),所述琥珀酸钠缓冲液为50mM的琥珀酸钠缓冲溶液,其pH值为5.2~5.5。
进一步的技术方案是,步骤(3),所述组氨酸缓冲溶液为5mM组氨酸缓冲溶液,其pH值为6.5~7.0。
进一步的技术方案是,步骤(3),所述第一次洗脱的流速为4~6ml/min。
进一步的技术方案是,步骤(3),所述第二次洗脱的流速为2~4ml/min。
与现有技术相比,本发明的有益效果是:
(1)采用本发明的方法,有效减少产物中杂质残留,进一步保证药物安全性,而且提高抗肿瘤活性。
(2)其中,本发明加入铜催化剂,有效促进hEnd-Apt和CD3单克隆抗体混合液与MAL-PEG2000-DSPE反应,显著提高反应效率,缩短反应时间,同时减少杂质产生,采用琥珀酸钠缓冲液、组氨酸缓冲溶液依次洗脱,充分去除未反应的适配体或抗体残留,有效减少杂质残留,提高目标产物收率以及纯度。
具体实施方式
为了更好理解本发明技术内容,下面提供具体实施例,对本发明做进一步的说明。
本发明实施例所用的实验方法如无特殊说明,均为常规方法。
本发明实施例所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
[Cu2(foac)2(phen)2]·10H2O的制备:采用现有方法制备:
取Cu(CH3COOH)2·H2O、邻菲罗啉和4-氟水杨酸按照摩尔比1:2:1加入无水甲醇中,料液比mol/L为1:5,搅拌均匀后,转移至带聚四氟乙烯衬底的水热反应釜中,并用三乙胺调pH值为6后密闭,加热至80℃反应120h,反应后室温条件下自然冷却,过滤并洗涤,制得[Cu2(foac)2(phen)2]·10H2O。
琥珀酸钠缓冲液为琥珀酸钠-琥珀酸缓冲液。
组氨酸缓冲溶液为组氨酸-醋酸盐缓冲液。
实施例1
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂双核铜配合物[Cu2(foac)2(phen)2]·10H2O,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,铜催化剂的加入量为混合液质量的1.5%,混合均匀,在氮气保护下反应18h;
(3)反应后采用50mM琥珀酸钠缓冲液(pH 5.5)进行第一次洗脱,洗脱流速为5ml/min;再以5mM组氨酸缓冲溶液(pH 6.8)进行第二次洗脱,洗脱流速为3ml/min;制得目标纳米复合物。
实施例2
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂双核铜配合物[Cu2(foac)2(phen)2]·10H2O,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,铜催化剂的加入量为混合液质量的1.3%,混合均匀,在氮气保护下反应20h;
(3)反应后采用50mM琥珀酸钠缓冲液(pH 5.5)进行第一次洗脱,洗脱流速为4ml/min;再以5mM组氨酸缓冲溶液(pH 6.5)进行第二次洗脱,洗脱流速为2ml/min;制得目标纳米复合物。
实施例3
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂双核铜配合物[Cu2(foac)2(phen)2]·10H2O,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,铜催化剂的加入量为混合液质量的1.8%,混合均匀,在氮气保护下反应15h;
(3)反应后采用50mM琥珀酸钠缓冲液(pH 5.2)进行第一次洗脱,洗脱流速为6ml/min;再以5mM组氨酸缓冲溶液(pH 7.0)进行第二次洗脱,洗脱流速为4ml/min;制得目标纳米复合物。
实施例4
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂双核铜配合物[Cu2(foac)2(phen)2]·10H2O,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,铜催化剂的加入量为混合液质量的0.5%,混合均匀,在氮气保护下反应18h;
(3)反应后采用50mM琥珀酸钠缓冲液(pH 5.5)进行第一次洗脱,洗脱流速为5ml/min;再以5mM组氨酸缓冲溶液(pH 6.8)进行第二次洗脱,洗脱流速为3ml/min;制得目标纳米复合物。
对比例1
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,与实施例1主要区别的是加入催化剂不同:
(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和醋酸钯催化剂,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,醋酸钯催化剂的加入量为混合液质量的1.5%,混合均匀,在氮气保护下反应18h;
(3)反应后采用50mM琥珀酸钠缓冲液(pH 5.5)进行第一次洗脱,洗脱流速为5ml/min;再以5mM组氨酸缓冲溶液(pH 6.8)进行第二次洗脱,洗脱流速为3ml/min;制得目标纳米复合物。
对比例2
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,与实施例1主要区别的是加入缓冲液不同:
一种hEnd-AptCD3-Lipo纳米复合物的制备方法,包括以下步骤:(1)将hEnd-Apt和CD3单克隆抗体按照摩尔比2:1混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂双核铜配合物[Cu2(foac)2(phen)2]·10H2O,其中,MAL-PEG2000-DSPE的质量浓度为10g/L,混合液和MAL-PEG2000-DSPE的体积比为1:10,铜催化剂的加入量为混合液质量的1.5%,混合均匀,在氮气保护下反应18h;
(3)反应后采用悬浮液(50mM Tris-HCl,140mM氯化钠,pH=7)洗脱,洗脱流速为4ml/min,制得目标纳米复合物。
试验例
1毒性测试
待测样品溶液配置:分别将实施例1-4以及对比例1-2所制的纳米复合物,分别制成浓度为1nM、10nM、100nM、500nM或1000nM的样品溶液。
将293T细胞、A549细胞与1nM、10nM、100nM、500nM或1000nM的样品溶液在RPMI1640完全培养基(含10%FBS)中孵育24、48小时,分别在24h、48h检测细胞的活性,使用CCK-8试剂盒测定细胞活力。结果显示该纳米复合物对293T细胞和A549细胞均无毒性。
2抗肿瘤活性测试
采用实施例1-4以及对比例1-2所制得纳米复合物修饰的PD-1-T细胞组对HepG2肝癌细胞的杀伤活性,设置效靶比10:1,考察实施例1-4以及对比例1-2所制得纳米复合物修饰的PD-1-T细胞组对靶细胞HepG2细胞的杀伤活性,对照组:PD-1-T细胞。抗肿瘤活性提高百分比=(药物组-对照组)/对照组*100%结果如下表1:
表1抗肿瘤活性测试结果
上述结果表明,实施例1-4以及对比文件1-2所制的纳米复合物修饰PD-1-T细胞对HepG2肿瘤细胞均具有较强的杀伤活性。其中,实施例1-4的杀伤活性更强。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (1)
1.一种hEnd-AptCD3-Lipo纳米复合物的制备方法,其特征在于,包括以下步骤:
(1)将hEnd-Apt和CD3单克隆抗体混合,得到混合液;
(2)在所述混合液中加入MAL-PEG2000-DSPE和铜催化剂,混合均匀,在氮气保护下反应;
(3)反应后采用琥珀酸钠缓冲液进行第一次洗脱,再以组氨酸缓冲溶液进行第二次洗脱,制得hEnd-AptCD3-Lipo纳米复合物;
步骤(1),所述hEnd-Apt和CD3单克隆抗体的摩尔比为2:0.9~1.1;
步骤(2),所述铜催化剂为双核铜配合物[Cu2(foac)2(phen)2]·10H2O;
步骤(2),所述MAL-PEG2000-DSPE的质量浓度为9~11g/L,所述混合液和MAL-PEG2000-DSPE的体积比为1:10~11;
步骤(2),所述铜催化剂的加入量为所述混合液质量的1%~2%;
步骤(2),反应时间为15~20h;
步骤(3),所述琥珀酸钠缓冲液为50 mM的琥珀酸钠缓冲溶液,其pH值为5.2~5.5;
步骤(3),所述组氨酸缓冲溶液为5 mM组氨酸缓冲溶液,其pH值为6.5~7.0;
步骤(3),所述第一次洗脱的流速为4~6ml/min;
步骤(3),所述第二次洗脱的流速为2~4ml/min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310471576.5A CN116510009B (zh) | 2023-04-27 | 2023-04-27 | 一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310471576.5A CN116510009B (zh) | 2023-04-27 | 2023-04-27 | 一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116510009A CN116510009A (zh) | 2023-08-01 |
CN116510009B true CN116510009B (zh) | 2023-12-15 |
Family
ID=87400591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310471576.5A Active CN116510009B (zh) | 2023-04-27 | 2023-04-27 | 一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116510009B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258789A (zh) * | 2010-12-29 | 2011-11-30 | 海南医学院 | 小型化Endoglin抗体与阿霉素的偶联物及其制备方法 |
CN103936772A (zh) * | 2014-05-05 | 2014-07-23 | 河南理工大学 | 一种具有抗肿瘤活性的双核铜配合物的制备方法 |
CN107847444A (zh) * | 2015-05-26 | 2018-03-27 | 通用医疗公司 | 脂质体纳米构建体及其制备和使用方法 |
CN109481697A (zh) * | 2018-12-29 | 2019-03-19 | 广西医科大学 | 一种组合物、利用该组合物制备双特异性脂质体纳米复合物的方法及该纳米复合物的应用 |
CN111569085A (zh) * | 2020-05-08 | 2020-08-25 | 东南大学 | 一种模块化双特异性磁性纳米复合物及应用 |
CN112794862A (zh) * | 2019-11-14 | 2021-05-14 | 六盘水师范学院 | 长碳链苯基二羧酸基双核铜配合物的合成及抗肿瘤应用 |
-
2023
- 2023-04-27 CN CN202310471576.5A patent/CN116510009B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258789A (zh) * | 2010-12-29 | 2011-11-30 | 海南医学院 | 小型化Endoglin抗体与阿霉素的偶联物及其制备方法 |
CN103936772A (zh) * | 2014-05-05 | 2014-07-23 | 河南理工大学 | 一种具有抗肿瘤活性的双核铜配合物的制备方法 |
CN107847444A (zh) * | 2015-05-26 | 2018-03-27 | 通用医疗公司 | 脂质体纳米构建体及其制备和使用方法 |
CN109481697A (zh) * | 2018-12-29 | 2019-03-19 | 广西医科大学 | 一种组合物、利用该组合物制备双特异性脂质体纳米复合物的方法及该纳米复合物的应用 |
CN112794862A (zh) * | 2019-11-14 | 2021-05-14 | 六盘水师范学院 | 长碳链苯基二羧酸基双核铜配合物的合成及抗肿瘤应用 |
CN111569085A (zh) * | 2020-05-08 | 2020-08-25 | 东南大学 | 一种模块化双特异性磁性纳米复合物及应用 |
Non-Patent Citations (4)
Title |
---|
Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects;Shenxia Xie等;《Int J Nanomedicine》;第16卷;1017-1034 * |
Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy;Mark J A Schoonderwoerd等;《Clin Cancer Res》;第26卷(第14期);3831-3842 * |
辛伐他汀纳米脂质体对骨髓间充质干细胞成骨分化的影响;徐璐等;《北京大学学报(医学版)》;第46卷(第06期);883-888 * |
高血压合并糖尿病患者血清单核细胞趋化蛋白1及抵抗素和Apelin水平与血管内皮功能的相关性;王武等;《中华高血压杂志》;第28卷(第12期);1205-1207 * |
Also Published As
Publication number | Publication date |
---|---|
CN116510009A (zh) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111377983B (zh) | 一种β-烟酰胺单核苷酸的制备方法 | |
Hollis et al. | Aqueous chemistry of (2, 2', 2"-terpyridine) gold (III). Preparation and structures of chloro (2, 2', 2"-terpyridine) gold dichloride trihydrate ([Au (terpy) Cl] Cl2. 3H2O) and the mixed valence gold (I)-gold (III) salt bis [chloro (2, 2', 2"-terpyridine) gold] tris (dichloroaurate) tetrachloroaurate ([Au (terpy) Cl] 2 [AuCl2] 3 [AuCl4]) | |
CN111440124B (zh) | 一种5-氟尿嘧啶与咖啡酸的共晶及其制备方法 | |
CN107778383A (zh) | 一种舒更葡糖钠的精制方法 | |
CN110790712A (zh) | 一种5-氟尿嘧啶与l-苯丙氨酸的共晶及其制备方法 | |
CN116510009B (zh) | 一种hEnd-AptCD3-Lipo纳米复合物的制备方法及应用 | |
CN110105469A (zh) | 一种舒更葡糖钠杂质及其制备方法 | |
CN110698686B (zh) | 分离丙炔/丙烯混合气体的铽配位聚合物及其制备方法 | |
Imai et al. | Expedient chemical synthesis of sequence-specific 2', 5'-oligonucleotides | |
CN110317132B (zh) | 一种苯丁酸钠的制备方法 | |
CN113929703B (zh) | 一种依维莫司有关物质d的合成方法 | |
JP4453070B2 (ja) | 5’−グアニル酸ジナトリウム・5’−イノシン酸ジナトリウム混晶の製造法 | |
CN116023285A (zh) | 一种左卡尼汀相关杂质及其制备方法 | |
Churchill et al. | Synthesis, properties, and crystallographic characterization of a dinuclear. mu.-carbonato complex of cobalt (III):[(NH3) 3Co (. mu.-OH) 2 (. mu.-CO3) Co (NH3) 3] SO4. 5H2O | |
CN110054641B (zh) | 四氮唑乙酸铈含能配合物合成方法及其对hmx热分解的促进作用 | |
CN103664707A (zh) | 酸式硫酸-β-氨基酯及其合成方法和应用 | |
CN111138354A (zh) | 一种异烟肼的制备方法 | |
CN114276283B (zh) | 3-叠氮基-n-(3-氯-2-氰基苯基)-2-甲基-2-(苯基硒基)丙酰胺 | |
CN106831760A (zh) | 一种利奥西呱的制备方法 | |
Koutmos et al. | Synthesis and characterization of MoFe3S4 and Mo2Fe2S4 single cubanes | |
CN107129437A (zh) | 4-[(2-氯乙基-2-羟乙基)氨基-]-l-苯丙氨酸盐酸盐的制备方法与应用 | |
Chen et al. | Synthesis and novel crystal structure of (E, Z) 3-aminomethylene-1-ethyl-indol-2-one | |
CN117535278A (zh) | 一种固定化酶及利用该固定化酶制备d-阿洛糖的方法 | |
CN117164466A (zh) | 一种伊沙替康中间体的制备方法 | |
CN114213405A (zh) | Vegfr抑制剂替沃扎尼的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |